Pertuzumab-based regimens and FOLFIRINOX are cost-effective for specific cancers while neoadjuvant pembrolizumab is not
New data shows cost-effectiveness of specific cancer drug regimens
This systematic review evaluates the cost-effectiveness of neoadjuvant regimens for breast, bladder, and pancreatic cancers. It finds pertuz…
New research identifies which cancer treatments are cost-effective, helping doctors and patients navigate the high costs of advanced care.
UFT combined with radiotherapy achieves a 38% pooled objective response rate in advanced pancreatic cancer
UFT Combined with Radiotherapy Shows Promise for Pancreatic Cancer
This meta-analysis of observational studies evaluates UFT combined with radiotherapy for patients with advanced pancreatic cancer. The analy…
A review of observational data suggests that combining UFT with radiotherapy may improve response rates for patients with advanced pancreati…
Fatty pancreas prevalence 30.5% and linked to higher pancreatitis, cancer risk
Fatty pancreas is linked to higher risk of pancreatic cancer
This meta-analysis of 124 studies including 141,416 healthy or routine-examination participants found a fatty pancreas prevalence of 30.5%, …
A fatty pancreas is common and linked to a higher risk of serious conditions like pancreatic cancer and diabetes.
High NLRP-3 Expression Linked to Poor Survival in Solid Cancers
High NLRP-3 levels linked to worse outcomes in solid cancers
Meta-analysis shows high NLRP-3 expression predicts worse overall and disease-free survival in solid tumors, with HR 2.12 for OS.
Higher levels of the NLRP-3 protein are linked to shorter survival times and more advanced disease in several types of solid tumors.
Genetic liability for cannabis use is causally linked to increased risk of esophageal and lung cancers
Genetic data reveals link between cannabis use and certain cancers
This meta-analysis using two-sample Mendelian Randomization evaluates the causal link between genetic liability to cannabis use and specific…
New research using genetic markers shows that a person's genetic tendency toward cannabis use may impact risks for lung, esophageal, and pan…
PDAC risk prediction models for new-onset diabetes patients show a pooled C-index of 0.78
New Models Predict Pancreatic Cancer Risk in New-Onset Diabetes
This meta-analysis of 14 studies involving 17 prediction models evaluated PDAC risk in patients with new-onset diabetes. The analysis found …
Researchers identified prediction models that can help identify the risk of pancreatic cancer in patients recently diagnosed with new-onset …
Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
Protein D shows promise in diagnosing and treating several cancers
This narrative review explores the role of Surfactant protein D (SP-D) across multiple malignancies, including lung adenocarcinoma and breas…
A specific protein called Surfactant protein D may help doctors identify lung cancer and fight cells in breast and leukemia cases.
New-onset diabetes and preoperative hyperglycemia predict worse survival in pancreatic ductal adenocarcinoma
Metformin use linked to better survival in pancreatic cancer
This meta-analysis of cohort studies evaluates the impact of glycemic status and metformin use on overall survival in patients with pancreat…
New research shows that patients with pancreatic cancer taking metformin may have a lower risk of death compared to those who do not.
Multidisciplinary team management reduces mortality risk in patients with hepatobiliary and pancreatic malignancies
Multidisciplinary teams linked to better outcomes for pancreatic and liver cancers
This meta-analysis of 70,294 patients found that multidisciplinary team (MDT) management significantly reduced mortality risk in both pancre…
A large review suggests that coordinated team care can improve survival rates and reduce complications for patients with complex liver and p…
Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months
Trial shows daraxonrasib improves survival for pancreatic cancer patients
This Phase 3 randomized trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma found daraxonrasib signifi…
A Phase 3 trial found that daraxonrasib significantly extended survival times for patients with specific types of metastatic pancreatic canc…
Mistletoe extract plus standard treatment shows no quality of life benefit in advanced pancreatic cancer
Trial shows mistletoe extract does not improve pancreatic cancer care
This Phase III randomized controlled trial evaluated mistletoe extract combined with standard care in 290 patients with advanced pancreatic …
A large trial found that adding mistletoe extract to standard treatment did not improve quality of life or weight for patients with advanced…
High red meat consumption increases pancreatic cancer risk by 16% in large population meta-analysis
High Red Meat Consumption Linked to Increased Pancreatic Cancer Risk
This meta-analysis of 1,959,527 participants found that the highest levels of red meat consumption are associated with a 16% increased risk …
New data suggests that eating more red meat may increase your risk of pancreatic cancer, while no link was found for processed meats.
Questions about Pancreatic Cancer
Is there a link between Periodontal Disease and pancreatic cancer in older adults?
Yes, research suggests periodontal disease is linked to a higher risk of pancreatic cancer in older adults, possibly due to chronic inflammation and oral bacteria.
Full answer →Does the protein OTUD7B promote the growth of tumors in pancreatic cancer?
Yes, OTUD7B promotes pancreatic cancer growth by stabilizing oncoproteins and activating signaling pathways like Notch and EGFR/MAPK.
Full answer →Is EGCG a potential treatment for digestive system diseases like pancreatic cancer?
EGCG shows promise against pancreatic cancer in lab and animal studies, but human trials are lacking, so it is not yet a proven treatment.
Full answer →What environmental factors and genetic risks contribute to the development of pancreatic cancer?
Pancreatic cancer risk comes from modifiable factors like smoking, obesity, and heavy drinking, plus inherited mutations in genes such as BRCA1/2 and PALB2.
Full answer →Can DNA damage response inhibitors overcome drug resistance in pancreatic cancer?
Yes, DNA damage response inhibitors can help overcome drug resistance in pancreatic cancer, especially when combined with other therapies, but single-agent use has limitations.
Full answer →All Pancreatic Cancer Articles
- Pertuzumab-based regimens and FOLFIRINOX are cost-effective for specific cancers while neoadjuvant pembrolizumab is not
- UFT combined with radiotherapy achieves a 38% pooled objective response rate in advanced pancreatic cancer
- Fatty pancreas prevalence 30.5% and linked to higher pancreatitis, cancer risk
- Genetic liability for cannabis use is causally linked to increased risk of esophageal and lung cancers
- High NLRP-3 Expression Linked to Poor Survival in Solid Cancers
- PDAC risk prediction models for new-onset diabetes patients show a pooled C-index of 0.78
- Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
- New-onset diabetes and preoperative hyperglycemia predict worse survival in pancreatic ductal adenocarcinoma
- Multidisciplinary team management reduces mortality risk in patients with hepatobiliary and pancreatic malignancies
- Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months
- Mistletoe extract plus standard treatment shows no quality of life benefit in advanced pancreatic cancer
- High red meat consumption increases pancreatic cancer risk by 16% in large population meta-analysis
- Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer
- Reverse-bevel ProCore FNB provides diagnostic yield comparable to standard FNA for pancreatic mass lesions
- Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types
- Meta-analysis Evaluating Occupational Hexavalent Chromium Exposure and Specific Malignancy Risks
- Cadmium exposure increases pancreatic cancer risk with an RR of 1.69 across meta-analyzed data
- Intratumoral microbiome linked to survival and chemotherapy resistance in pancreatic cancer
- Combination strategies using DNA damage response inhibitors aim to overcome resistance in pancreatic cancer
- Pancreatic cancer involves multilayered mechanisms from environment to immune escape
- Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
- OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
- Meta-analysis quantifies pre-diagnosis weight loss in pancreatic cancer patients
- Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost
- AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods
- Meta-analysis shows percutaneous irreversible electroporation plus immunotherapy improves outcomes in locally advanced pancreatic cancer
- Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
- Systematic review identifies 16 mRNA vaccine antigens for pancreatic cancer immunotherapy
- Perioperative Propranolol and Etodolac Safety and 8-Year Survival in Cancer Patients
- SCOPE platform predicts outcomes for metastatic colorectal and pancreatic cancers using organoid screening
- Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer